Warrant holder Andrew Schwartzberg seeks more than $3.1 million from Gain and Gene Mack for breach of contract, fraudulent inducement and promissory estoppel. Gain's 10-Q reports going concern doubt.
Gain agreed to sell 4,501,640 shares and warrants for 2,250,820 shares at $3.11 per set through Newbridge Securities. It expects net proceeds of approximately $6.3 million, with closing expected on or about July 17, 2025.
Gain Therapeutics received a Nasdaq deficiency notice on January 8, 2025 over its Market Value of Listed Securities. Nasdaq staff confirmed in writing on January 15 that the company is back in compliance.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $13.1 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Gain Therapeutics
Has Gain Therapeutics issued a going-concern warning?
Our latest story on this, dated Aug 11, 2026: "Gain Therapeutics and CEO Gene Mack sued in Delaware over warrant exercise price". The story links the filing or release it is based on. Read the story.
Has Gain Therapeutics raised money recently?
Our latest story on this, dated Jul 17, 2025: "Gain Therapeutics prices public offering of shares and warrants for $7.0 million gross proceeds". The story links the filing or release it is based on. Read the story.
Has Gain Therapeutics received a Nasdaq deficiency notice?
Our latest story on this, dated Jan 15, 2025: "Gain Therapeutics regains compliance with Nasdaq $50 million market value requirement". The story links the filing or release it is based on. Read the story.
Is Gain Therapeutics involved in a lawsuit?
Our latest story on this, dated Aug 11, 2026: "Gain Therapeutics and CEO Gene Mack sued in Delaware over warrant exercise price". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Gain Therapeutics?
Gain Therapeutics, Inc. trades under the ticker GANX on NASDAQ.
Where is Gain Therapeutics listed?
Gain Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Gain Therapeutics?
The SEC Central Index Key (CIK) for Gain Therapeutics, Inc. is 1819411. Its filings are on SEC EDGAR.
How many shares does Gain Therapeutics have outstanding?
43,643,619 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-11.
Which country or territory is Gain Therapeutics listed under?
Our directory records Gain Therapeutics, Inc. under United States.
What does Gain Therapeutics do?
Our directory classifies Gain Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Gain Therapeutics?
The ISIN recorded for Gain Therapeutics, Inc. is US36269B1052.
Does aibio.space cover Gain Therapeutics?
aibio.space lists Gain Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Gain Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Gain Therapeutics profitable?
Gain Therapeutics, Inc. reported a net loss of $20.2 million for the fiscal year ended Dec 31, 2025, and used $18.5 million of cash in operations, per its annual report to the SEC.
How much does Gain Therapeutics spend on research and development?
$10.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: Gain Therapeutics
Members talk about Gain Therapeutics (GANX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Gain Therapeutics, newest first. Each line links the filing it comes from.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:GANX on TradingView.
SEC filings and registration
SEC name
Gain Therapeutics, Inc.
CIK
1819411
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
GANX (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
4800 HAMPDEN LANE, BETHESDA, MD, 20814
Phone
(301) 500-1556
Shares outstanding
43,643,619 as of 2026-07-31 (10-Q filed 2026-08-11)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Gain Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GANX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio